| Clarifying confusion: the confusion assessment method: a new method for detection of delirium SK Inouye, CH van Dyck, CA Alessi, S Balkin, AP Siegal, RI Horwitz Annals of internal medicine 113 (12), 941-948, 1990 | 6583 | 1990 |
| Lecanemab in early Alzheimer’s disease CH Van Dyck, CJ Swanson, P Aisen, RJ Bateman, C Chen, M Gee, ... New England Journal of Medicine 388 (1), 9-21, 2023 | 3162 | 2023 |
| Vitamin E and donepezil for the treatment of mild cognitive impairment RC Petersen, RG Thomas, M Grundman, D Bennett, R Doody, S Ferris, ... New England Journal of Medicine 352 (23), 2379-2388, 2005 | 2506 | 2005 |
| Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. M Laruelle, A Abi-Dargham, CH Van Dyck, R Gil, CD D'Souza, J Erdos, ... Proceedings of the National Academy of Sciences 93 (17), 9235-9240, 1996 | 1658 | 1996 |
| Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial RA Mulnard, CW Cotman, C Kawas, CH Van Dyck, M Sano, R Doody, ... Jama 283 (8), 1007-1015, 2000 | 1329 | 2000 |
| Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials M Grundman, RC Petersen, SH Ferris, RG Thomas, PS Aisen, DA Bennett, ... Archives of neurology 61 (1), 59-66, 2004 | 1268 | 2004 |
| Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort A Abi-Dargham, R Gil, J Krystal, RM Baldwin, JP Seibyl, M Bowers, ... American journal of psychiatry 155 (6), 761-767, 1998 | 1143 | 1998 |
| A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease S Salloway, R Sperling, S Gilman, NC Fox, K Blennow, M Raskind, ... Neurology 73 (24), 2061-2070, 2009 | 930 | 2009 |
| Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial JF Quinn, R Raman, RG Thomas, K Yurko-Mauro, EB Nelson, C Van Dyck, ... Jama 304 (17), 1903-1911, 2010 | 926 | 2010 |
| A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease RS Turner, RG Thomas, S Craft, CH Van Dyck, J Mintzer, BA Reynolds, ... Neurology 85 (16), 1383-1391, 2015 | 693 | 2015 |
| High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial PS Aisen, LS Schneider, M Sano, R Diaz-Arrastia, CH Van Dyck, ... Jama 300 (15), 1774-1783, 2008 | 671 | 2008 |
| Reduced brain serotonin transporter availability in major depression as measured by [123I]-2β-carbomethoxy-3β-(4-iodophenyl) tropane and single photon emission computed tomography RT Malison, LH Price, R Berman, CH van Dyck, GH Pelton, L Carpenter, ... Biological psychiatry 44 (11), 1090-1098, 1998 | 643 | 1998 |
| Anti-amyloid-β monoclonal antibodies for Alzheimer’s disease: pitfalls and promise CH Van Dyck Biological psychiatry 83 (4), 311-319, 2018 | 609 | 2018 |
| Randomized trial of verubecestat for prodromal Alzheimer’s disease MF Egan, J Kost, T Voss, Y Mukai, PS Aisen, JL Cummings, PN Tariot, ... New England Journal of Medicine 380 (15), 1408-1420, 2019 | 570 | 2019 |
| [sup 123 I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease KL Marek, JP Seibyl, SS Zoghbi, Y Zea-Ponce, RM Baldwin, B Fussell, ... Neurology 46 (1), 231-237, 1996 | 464 | 1996 |
| Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease V Coric, CH Van Dyck, S Salloway, N Andreasen, M Brody, RW Richter, ... Archives of neurology 69 (11), 1430-1440, 2012 | 453 | 2012 |
| SPECT imaging of striatal dopamine release after amphetamine challenge M Laruelle, A Abi-Dargham, CH van Dyck, W Rosenblatt, Y Zea-Ponce, ... Journal of Nuclear Medicine 36 (7), 1182-1190, 1995 | 436 | 1995 |
| [123I]β-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression K Marek, R Innis, C Van Dyck, B Fussell, M Early, S Eberly, D Oakes, ... Neurology 57 (11), 2089-2094, 2001 | 429 | 2001 |
| Assessing synaptic density in Alzheimer disease with synaptic vesicle glycoprotein 2A positron emission tomographic imaging MK Chen, AP Mecca, M Naganawa, SJ Finnema, T Toyonaga, S Lin, ... JAMA neurology 75 (10), 1215-1224, 2018 | 399 | 2018 |
| A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease M Sano, KL Bell, D Galasko, JE Galvin, RG Thomas, CH Van Dyck, ... Neurology 77 (6), 556-563, 2011 | 386 | 2011 |
